Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Chubb
Accenture
Healthtrust
Teva
Dow
Colorcon
US Department of Justice
Federal Trade Commission

Generated: February 19, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR VANDETANIB

« Back to Dashboard

Clinical Trials for Vandetanib

Trial ID Title Status Sponsor Phase Summary
NCT00066313 ZD6474 in Treating Patients With Small Cell Lung Cancer Completed Genzyme, a Sanofi Company Phase 2 RATIONALE: ZD6474 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. ZD6474 may also stop the growth of small cell lung cancer by blocking blood flow to the tumor. PURPOSE: This randomized phase II trial is studying how well ZD6474 works compared to placebo in treating patients with small cell lung cancer that has responded to previous chemotherapy with or without radiation therapy.
NCT00290537 Phase II Study of ZD6474 in Advanced NSCLC Terminated AstraZeneca Phase 2 The goal of this clinical research study is to learn how the drug ZD6474 affects the amount of tumor cell death in the body and the amount of blood that can be supplied to the tumor. The safety of ZD6474 alone and when given with chemotherapy will be studied. In addition, the side effects and response to this treatment will also be studied.
NCT00290537 Phase II Study of ZD6474 in Advanced NSCLC Terminated M.D. Anderson Cancer Center Phase 2 The goal of this clinical research study is to learn how the drug ZD6474 affects the amount of tumor cell death in the body and the amount of blood that can be supplied to the tumor. The safety of ZD6474 alone and when given with chemotherapy will be studied. In addition, the side effects and response to this treatment will also be studied.
NCT00312377 ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer Completed Genzyme, a Sanofi Company Phase 3 This large phase III clinical study is studying the effect of vandetanib (ZACTIMA) in treating non-small cell lung cancer (NSCLC). Vandetanib is a new type of agent that targets the blood supply to a cancer tumour (through it's anti-vascular endothelial growth factor receptor (VEGFR) properties) and the tumour cells themselves (through it's anti-endothelial growth factor receptor (EGFR) actions). This study will look at the effects of vandetanib in lung cancer patients who have had their cancer re-appear after treatment with standard chemotherapy. This clinical study will test if the vandetanib anti-VEGF and anti-EGFR characteristics can deliver longer improved progression free survival and improved overall survival than docetaxel (Taxotere) alone. All patients participating this clinical study will receive treatment with docetaxel, a commonly used treatment for recurrent non-small cell lung cancer. In addition, some patients will also receive vandetanib (ZACTIMA), an anti-EGFR / anti-VEGF agent. Recent clinical research shows that vascular endothelial growth factor receptor (VEGFR) inhibition, when used with standard chemotherapy, can lead to increased survival in advanced non-small cell lung cancer (NSCLC) patients. Other research shows that epidermal growth factor receptor (EGFR) inhibitors, like erlotinib (Tarceva) can also increase overall non-small cell lung cancer survival by killing tumour cells and stopping them from dividing.
NCT00364351 Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy Active, not recruiting Genzyme, a Sanofi Company Phase 3 To determine if ZD6474 a new investigational drug, is effective in treating Non Small Lung Cancer and if so, how it compares with another type of anti cancer therapy chemotherapy, Erlotinib
NCT00410189 BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC Completed AstraZeneca Phase 2 Primary Objective: - To determine the 8 week progression-free survival rate (i.e. disease control rate) in patients with advanced NSCLC who have failed at least one prior chemotherapy regimen. Secondary Objectives: - Determine the overall response rate - Determine the overall survival - Determine the time to disease progression - Assess the safety/toxicity of the study treatment - Assess biomarker modulation in the tumor tissue and serum samples from the treatment - Assess plasma and intra-tumor concentrations of study treatment
NCT00410189 BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC Completed United States Department of Defense Phase 2 Primary Objective: - To determine the 8 week progression-free survival rate (i.e. disease control rate) in patients with advanced NSCLC who have failed at least one prior chemotherapy regimen. Secondary Objectives: - Determine the overall response rate - Determine the overall survival - Determine the time to disease progression - Assess the safety/toxicity of the study treatment - Assess biomarker modulation in the tumor tissue and serum samples from the treatment - Assess plasma and intra-tumor concentrations of study treatment
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Vandetanib

Condition Name

Condition Name for Vandetanib
Intervention Trials
Lung Cancer 10
Non Small Cell Lung Cancer 6
Prostate Cancer 4
Cancer 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Vandetanib
Intervention Trials
Lung Neoplasms 21
Carcinoma, Non-Small-Cell Lung 14
Thyroid Neoplasms 12
Thyroid Diseases 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Vandetanib

Trials by Country

Trials by Country for Vandetanib
Location Trials
United States 179
Canada 32
Italy 31
United Kingdom 22
Germany 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Vandetanib
Location Trials
Maryland 15
Texas 12
New York 10
Kansas 9
Michigan 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Vandetanib

Clinical Trial Phase

Clinical Trial Phase for Vandetanib
Clinical Trial Phase Trials
Phase 4 1
Phase 3 5
Phase 2 41
[disabled in preview] 39
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Vandetanib
Clinical Trial Phase Trials
Completed 36
Recruiting 16
Terminated 15
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Vandetanib

Sponsor Name

Sponsor Name for Vandetanib
Sponsor Trials
AstraZeneca 26
Genzyme, a Sanofi Company 22
National Cancer Institute (NCI) 18
[disabled in preview] 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Vandetanib
Sponsor Trials
Other 69
Industry 59
NIH 20
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Covington
Cipla
Teva
Daiichi Sankyo
Fuji
Dow
Harvard Business School
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.